Depomed Company Profile (NASDAQ:DEPO)

About Depomed (NASDAQ:DEPO)

Depomed logoDepomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia. Its CAMBIA (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Generic Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:DEPO
  • CUSIP: 24990810
  • Web:
  • Market Cap: $690.69 million
  • Outstanding Shares: 62,341,000
Average Prices:
  • 50 Day Moving Avg: $10.51
  • 200 Day Moving Avg: $13.69
  • 52 Week Range: $9.38 - $27.02
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -115.33
  • P/E Growth: 0.70
Sales & Book Value:
  • Annual Revenue: $441.56 million
  • Price / Sales: 1.47
  • Book Value: $3.69 per share
  • Price / Book: 2.81
  • EBIDTA: $125.09 million
  • Net Margins: -21.41%
  • Return on Equity: -25.33%
  • Return on Assets: -5.52%
  • Debt-to-Equity Ratio: 2.71%
  • Current Ratio: 0.95%
  • Quick Ratio: 0.91%
  • Average Volume: 1.50 million shs.
  • Beta: 1.15
  • Short Ratio: 6.48

Frequently Asked Questions for Depomed (NASDAQ:DEPO)

What is Depomed's stock symbol?

Depomed trades on the NASDAQ under the ticker symbol "DEPO."

How were Depomed's earnings last quarter?

Depomed, Inc. (NASDAQ:DEPO) released its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.18. The business had revenue of $95 million for the quarter, compared to analysts' expectations of $99.48 million. Depomed had a negative net margin of 21.41% and a negative return on equity of 25.33%. The company's quarterly revenue was down 9.2% on a year-over-year basis. During the same period last year, the business earned $0.04 earnings per share. View Depomed's Earnings History.

When will Depomed make its next earnings announcement?

Depomed is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Depomed.

Where is Depomed's stock going? Where will Depomed's stock price be in 2017?

8 brokers have issued 1 year price objectives for Depomed's shares. Their forecasts range from $10.00 to $26.00. On average, they anticipate Depomed's stock price to reach $17.00 in the next twelve months. View Analyst Ratings for Depomed.

What are analysts saying about Depomed stock?

Here are some recent quotes from research analysts about Depomed stock:

  • 1. Cantor Fitzgerald analysts commented, "After the March 28 close, DEPO announced an agreement with Starboard that replaces CEO Jim Schoeneck as well as two incumbent board members. Guidance for 1Q17 revenue was also released, $95-100M vs. FactSet estimate." (3/29/2017)
  • 2. Janney Montgomery Scott analysts commented, "Recent developments in the 2013 patent litigation brought by DEPO against Purdue have resulted in DEPO filing an amended complaint claiming Purdue willfully violated its patents. The dispute pertains to DEPO's claim that Purdue's abuse-deterrent formulation of OxyContin, which was approved by the FDA on April 5, 2010 and subsequently commercialized, relies on inventions protected by patents for DEPO's Acuform?? drug delivery technology. With a potential royalty on cumulative net sales of $10 billion at stake, we have previously estimated, and continue to believe, a damage award of $200 million or more is possible, with little to no downside risk to DEPO in the process. We note our prior estimate did not contemplate an enhanced damage award that may result in a treble (3x) damages if DEPO prevails." (2/27/2017)
  • 3. Mizuho analysts commented, "We had expected some benefit from stocking in the quarter that did not materialize. Mgmt also lowered its FY:16 revenue guidance from $490-$520M to $480-$505M and tightened its earnings guidance towards the lower end of the prior range (non-GAAP adjusted Earnings are now $95-$105M, down from $95-$115M previously). We were modeling $488.8M in revenues and $84M in net income so the lowered guide is ultimately not that surprising. We will revisit our Buy rating and $23 PT after the earnings call. Product updates: Nucynta/ER sales of $71.9M (26.9% Y/Y growth) missed consensus estimates of $75.5M. Gralise revenues came in at $23.8M relative to $22.1M consensus, growing 13.7% Y/Y. We view this uptick as a sign that mgmt’s efforts to revitalize the brand have been somewhat effective. Zipsor sales of $6.8M (+13.8% Y/Y) beat consensus estimates of $6.4M due to the introduction of a 120 pill bottle (that led to a higher pill count or greater value per prescription). Cambia sales of $7.6M missed consensus estimates of $8.2M but the brand is still growing 11.2% Y/Y. Finally, Lazanda sales of $6.4M beat consensus estimates of $5.8M, and the brand grew 64.9% Y/Y. Activist updates: We expect an investor presentation from Starboard Value during its proxy solicitation period that could drive additional momentum in the stock." (8/4/2016)

Are investors shorting Depomed?

Depomed saw a decrease in short interest in the month of June. As of June 15th, there was short interest totalling 11,036,089 shares, a decrease of 12.1% from the May 31st total of 12,559,484 shares. Based on an average daily trading volume, of 1,531,458 shares, the days-to-cover ratio is currently 7.2 days. Approximately 18.0% of the company's stock are sold short.

Who are some of Depomed's key competitors?

Who are Depomed's key executives?

Depomed's management team includes the folowing people:

  • James P. Fogarty CPA, Chairman of the Board
  • Arthur J. Higgins, President, Chief Executive Officer, Director
  • August J. Moretti, Chief Financial Officer, Senior Vice President
  • Matthew M. Gosling, Senior Vice President, General Counsel
  • Sharon D. Larkin, Senior Vice President - Human Resources and Administration.
  • Gerd G. Kochendoerfer, Senior Vice President, Technical Development & Quality
  • Srinivas Gandham Rao M.D. Ph.D., Chief Medical Officer and Senior Vice President
  • Thadd M. Vargas, Senior Vice President - Business Development
  • Karen A. Dawes, Independent Director
  • Louis J. Lavigne Jr., Independent Director

Who owns Depomed stock?

Depomed's stock is owned by a number of of retail and institutional investors. Top institutional investors include STARBOARD VALUE LP (8.70%), Creative Planning (0.06%), Louisiana State Employees Retirement System (0.04%), Fox Run Management L.L.C. (0.04%), Franklin Street Advisors Inc. NC (0.03%) and Aperio Group LLC (0.03%). Company insiders that own Depomed stock include Arthur J Higgins, August J Moretti and Thadd M Vargas. View Institutional Ownership Trends for Depomed.

Who sold Depomed stock? Who is selling Depomed stock?

Depomed's stock was sold by a variety of institutional investors in the last quarter, including Capstone Asset Management Co. and Creative Planning. Company insiders that have sold Depomed stock in the last year include August J Moretti and Thadd M Vargas. View Insider Buying and Selling for Depomed.

Who bought Depomed stock? Who is buying Depomed stock?

Depomed's stock was acquired by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C., Aperio Group LLC, State of Alaska Department of Revenue and Louisiana State Employees Retirement System. View Insider Buying and Selling for Depomed.

How do I buy Depomed stock?

Shares of Depomed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Depomed's stock price today?

One share of Depomed stock can currently be purchased for approximately $10.38.

MarketBeat Community Rating for Depomed (NASDAQ DEPO)
Community Ranking:  3.1 out of 5 (  )
Outperform Votes:  303 (Vote Outperform)
Underperform Votes:  190 (Vote Underperform)
Total Votes:  493
MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Depomed (NASDAQ:DEPO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $17.00 (63.78% upside)

Analysts' Ratings History for Depomed (NASDAQ:DEPO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/16/2017Royal Bank Of CanadaSet Price TargetHold$13.00LowView Rating Details
5/25/2017MizuhoLower Price TargetNeutral$13.00 -> $11.00MediumView Rating Details
5/15/2017Cantor FitzgeraldSet Price TargetHold$14.00MediumView Rating Details
5/10/2017Piper Jaffray CompaniesUpgradeUnderweight -> Neutral$11.00 -> $10.00HighView Rating Details
4/11/2017Janney Montgomery ScottReiterated RatingBuy$26.00LowView Rating Details
3/30/2017JMP SecuritiesReiterated RatingOutperform$30.00 -> $16.00HighView Rating Details
2/18/2017Roth CapitalSet Price TargetBuy$24.00N/AView Rating Details
11/8/2016Leerink SwannSet Price TargetBuy$22.00N/AView Rating Details
3/24/2016Northland SecuritiesInitiated CoverageOutperform$22.00N/AView Rating Details
2/24/2016WallachBeth CapitalLower Price TargetBuy$33.00 -> $27.00N/AView Rating Details
12/3/2015Morgan StanleyInitiated CoverageEqual -> Equal Weight$21.00N/AView Rating Details
(Data available from 7/20/2015 forward)


Earnings History for Depomed (NASDAQ:DEPO)
Earnings by Quarter for Depomed (NASDAQ:DEPO)
Earnings History by Quarter for Depomed (NASDAQ DEPO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017$0.09N/AView Earnings Details
5/9/2017Q1 2017($0.25)($0.43)$99.48 million$95.00 millionViewListenView Earnings Details
2/21/2017Q4 2016$0.36$0.48$123.00 million$123.90 millionViewListenView Earnings Details
11/7/2016Q3$0.35$0.28$127.22 million$111.00 millionViewListenView Earnings Details
8/3/2016Q2$0.26$0.27$118.20 million$116.70 millionViewListenView Earnings Details
5/5/2016Q1$0.17$0.12$106.88 million$104.60 millionViewListenView Earnings Details
2/22/2016Q415$0.29$0.16$110.19 million$111.20 millionViewListenView Earnings Details
11/9/2015Q3$0.19$0.33$101.64 million$105.00 millionViewListenView Earnings Details
7/29/2015Q215($0.45)$0.27$88.33 million$94.30 millionViewListenView Earnings Details
5/11/2015Q115$0.07($0.13)$33.80 million$31.70 millionViewListenView Earnings Details
2/23/2015Q414$0.07$0.21$44.66 million$33.90 millionViewListenView Earnings Details
11/5/2014Q314($0.04)($0.01)$41.50 million$51.49 millionViewListenView Earnings Details
8/6/2014Q214($0.06)($0.03)$38.03 million$67.70 millionViewListenView Earnings Details
5/8/2014Q114$0.11($0.04)$53.57 million$76.50 millionViewListenView Earnings Details
3/12/2014Q413($0.21)$0.72$19.06 million$40.60 millionViewListenView Earnings Details
11/5/2013Q313$0.07$0.11$35.55 million$37.50 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.05)$0.01$29.87 million$30.00 millionViewListenView Earnings Details
5/8/2013Q1 2013($0.06)($0.10)$28.93 million$26.20 millionViewListenView Earnings Details
2/20/2013Q4 2012($0.11)($0.07)$26.48 million$26.60 millionViewListenView Earnings Details
11/5/2012Q312($0.11)($0.03)$28.06 million$33.30 millionViewN/AView Earnings Details
8/2/2012($0.22)($0.28)ViewN/AView Earnings Details
5/8/2012($0.24)($0.16)ViewN/AView Earnings Details
3/8/2012($0.31)($0.25)ViewN/AView Earnings Details
11/1/2011($0.23)($0.15)ViewN/AView Earnings Details
8/1/2011($0.05)($0.11)ViewN/AView Earnings Details
5/5/2011$1.05$1.77ViewN/AView Earnings Details
3/3/2011$0.06$0.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Depomed (NASDAQ:DEPO)
2017 EPS Consensus Estimate: ($0.20)
2018 EPS Consensus Estimate: $0.38
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.25)($0.20)($0.23)
Q2 20172($0.32)($0.04)($0.18)
Q3 20172($0.05)$0.04($0.01)
Q4 20172$0.05$0.38$0.22
Q1 20181$0.03$0.03$0.03
Q2 20181$0.09$0.09$0.09
Q3 20181$0.12$0.12$0.12
Q4 20181$0.14$0.14$0.14
(Data provided by Zacks Investment Research)


Dividend History for Depomed (NASDAQ:DEPO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Depomed (NASDAQ:DEPO)
Insider Ownership Percentage: 5.12%
Institutional Ownership Percentage: 92.36%
Insider Trades by Quarter for Depomed (NASDAQ:DEPO)
Institutional Ownership by Quarter for Depomed (NASDAQ:DEPO)
Insider Trades by Quarter for Depomed (NASDAQ:DEPO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/12/2017Arthur J HigginsInsiderBuy15,000$9.92$148,800.00View SEC Filing  
11/14/2016August J MorettiCFOSell5,000$20.84$104,200.00View SEC Filing  
9/21/2016Thadd M VargasVPSell11,250$25.00$281,250.00View SEC Filing  
8/10/2016August J. MorettiCFOSell5,000$21.40$107,000.00View SEC Filing  
8/10/2016Thadd M VargasVPSell26,290$20.92$549,986.80View SEC Filing  
5/23/2016Thadd M VargasVPSell15,000$20.00$300,000.00View SEC Filing  
5/10/2016Thadd M VargasVPSell15,000$17.64$264,600.00View SEC Filing  
5/9/2016August J MorettiCFOSell5,000$18.00$90,000.00View SEC Filing  
3/11/2016Thadd M VargasVPSell23,000$16.00$368,000.00View SEC Filing  
12/3/2015August J. MorettiCFOSell15,000$18.11$271,650.00View SEC Filing  
6/12/2015Thadd M VargasVPSell5,000$20.70$103,500.00View SEC Filing  
12/2/2014August J MorettiCFOSell5,339$15.85$84,623.15View SEC Filing  
12/2/2014James A SchoeneckCEOSell36,727$15.85$582,122.95View SEC Filing  
12/2/2014Thadd M VargasVPSell8,247$15.85$130,714.95View SEC Filing  
11/19/2014Matthew M GoslingVPSell71,000$15.36$1,090,560.00View SEC Filing  
3/14/2014James SchoeneckCEOSell17,000$14.54$247,180.00View SEC Filing  
3/14/2014Matthew GoslingVPSell21,875$14.74$322,437.50View SEC Filing  
12/2/2013Michael Md SweeneyCMOSell4,270$8.40$35,868.00View SEC Filing  
12/2/2013Thadd VargasVPSell5,296$8.40$44,486.40View SEC Filing  
5/10/2013James A SchoeneckCEOBuy25,000$5.11$127,750.00View SEC Filing  
3/6/2013Karen A DawesDirectorBuy2,000$5.96$11,920.00View SEC Filing  
8/14/2012Peter D StapleDirectorBuy5,000$5.01$25,050.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Depomed (NASDAQ:DEPO)
Latest Headlines for Depomed (NASDAQ:DEPO)
DateHeadline logoDepomed's (NASDAQ:DEPO) "Hold" Rating Reiterated at Royal Bank Of Canada - July 16 at 7:33 AM logoComparing Depomed (DEPO) and Hospira (HSP) - July 13 at 8:28 PM logoForm 8-K DEPOMED INC For: Jul 13 - - July 13 at 7:08 PM logoDepomed Announces Intent to Effect a Debt Refinancing - July 13 at 7:07 PM logoDepomed, Inc. -- Moody's assigns B3 CFR to Depomed; stable outlook - July 13 at 7:07 PM logoMerus Labs International (MSLI) & Depomed (NASDAQ:DEPO) Financial Analysis - July 13 at 8:34 AM logoDepomed business development chief to retire at end of month with golden parachute - July 13 at 7:26 AM logoDepomed, Inc. breached its 50 day moving average in a Bearish Manner : DEPO-US : July 12, 2017 - July 12 at 6:28 PM logoReviewing Depomed (DEPO) & Merus Labs International (MSLI) - July 11 at 8:26 PM logoETFs with exposure to Depomed, Inc. : July 10, 2017 - July 10 at 5:49 PM logoBRIEF-Depomed chief medical officer Srinivas Rao resigns - Reuters - July 9 at 11:01 AM logoBRIEF-Depomed chief medical officer Srinivas Rao resigns - July 8 at 10:11 AM logoZacks: Analysts Anticipate Depomed, Inc. (DEPO) Will Post Quarterly Sales of $100.12 Million - July 6 at 9:16 AM logoCumberland Pharmaceuticals (CPIX) versus Depomed (NASDAQ:DEPO) Head to Head Analysis - July 5 at 8:27 AM logoZacks: Analysts Anticipate Depomed, Inc. (NASDAQ:DEPO) Will Announce Earnings of -$0.41 Per Share - July 5 at 12:22 AM logoDepomed, Inc. (DEPO) Sees Significant Drop in Short Interest - June 29 at 7:18 AM logoDepomed, Inc. (DEPO) Given Consensus Recommendation of "Hold" by Brokerages - June 27 at 10:42 PM logoETFs with exposure to Depomed, Inc. : June 27, 2017 - June 27 at 4:57 PM logoCritical Contrast: Depomed (DEPO) vs. Merus Labs International (MSLI) - June 26 at 2:26 PM logoCritical Contrast: Depomed (DEPO) and The Medicines Company (MDCO) - June 25 at 7:37 AM logoDepomed, Inc. breached its 50 day moving average in a Bullish Manner : DEPO-US : June 23, 2017 - June 23 at 5:19 PM logoDepomed's (DEPO) "Hold" Rating Reaffirmed at Royal Bank Of Canada - June 18 at 8:20 PM logoETFs with exposure to Depomed, Inc. : June 16, 2017 - June 16 at 5:28 PM logoDepomed, Inc. :DEPO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 - June 14 at 5:41 PM logoDepomed, Inc. :DEPO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 - June 14 at 5:41 PM logoArthur J. Higgins Acquires 15,000 Shares of Depomed, Inc. (DEPO) Stock - June 13 at 4:36 PM logoOpioid Stocks Threatened by FDA Steps (ENDP, DEPO, INSY) - June 12 at 5:40 PM logoDepomed, Insys Shares Down After FDA Decision on Endo's Opana ER - - June 10 at 9:55 PM logoDepomed Inc (DEPO) Expected to Post Quarterly Sales of $100.12 Million - June 10 at 7:34 AM logo-$0.41 EPS Expected for Depomed Inc (DEPO) This Quarter - June 9 at 12:08 AM logoDepomed Inc (DEPO) Raised to "Sell" at ValuEngine - June 4 at 8:36 PM logoDepomed Inc (DEPO) Receives Consensus Rating of "Hold" from Brokerages - June 2 at 12:46 PM logoScott+Scott, Attorneys At Law, LLP Announces Investigation Into OneMain Holdings, Inc. (OMF) - May 31 at 4:43 PM logoHow These Drug Makers Stocks are Faring? -- Depomed, Pernix Therapeutics ... - May 31 at 9:55 AM logoDepomed Inc (DEPO) Stock Rating Reaffirmed by Mizuho - May 25 at 9:52 PM logoShangPharma Innovation Appoints Mohamad Moghadam-Tabrizi as Senior Vice President of Business Development - May 24 at 12:36 PM logoBRIEF-Depomed announces corporate governance updates - May 22 at 11:59 AM logoDepomed Announces Corporate Governance Updates - May 22 at 11:59 AM logoDepomed Inc (DEPO) Given a $14.00 Price Target at Cantor Fitzgerald - May 15 at 3:15 PM logoDepomed Inc (DEPO) Upgraded to Neutral by Piper Jaffray Companies - May 14 at 6:28 PM logo Brokerages Expect Depomed Inc (DEPO) Will Post Quarterly Sales of $110.54 Million - May 14 at 8:50 AM logoZacks: Analysts Anticipate Depomed Inc (DEPO) to Announce -$0.35 Earnings Per Share - May 12 at 8:28 PM logoToday's Research Reports on Stocks to Watch: Rexahn Pharmaceuticals and Depomed - May 12 at 3:24 PM logoDepoMed Inc (DEPO) PT Lowered to $13 at RBC Capital; Magnitude of Reset was a Suprise - - May 11 at 5:21 PM logoDepomed Focuses on Flagship Drug Rather Than M&A: CEO - May 10 at 9:55 PM logoDepomed's (DEPO) "Sector Perform" Rating Reiterated at Royal Bank of Canada - May 10 at 6:28 PM logoBRIEF-Depomed reports Q1 adjusted non-GAAP earnings $0.07/shr - May 10 at 4:51 PM logoDepoMed Inc (DEPO) PT Lowered to $13 at RBC Capital; Magnitude of Reset was a Suprise - May 10 at 4:51 PM logoBiotech Movers: Depomed Shares Tank After Losses Get Even Worse - May 10 at 4:51 PM logoDepomed Q1 top line down 14%; loss widens; guidance lowered; shares sink 16% premarket - May 10 at 8:56 AM



Depomed (DEPO) Chart for Thursday, July, 20, 2017

This page was last updated on 7/20/2017 by Staff